Information Provided By:
Fly News Breaks for September 8, 2015
FOLD
Sep 8, 2015 | 07:20 EDT
JPMorgan analyst Anupam Rama raised his price target for Amicus Therapeutics to $28 saying it views the Scioderm acquisition as a "compelling pipeline addition" after speaking to academic dermatologists. Scioderm's lead drug Zorblisa, currently in Phase 3 for the treatment of Epidermolysis Bullosa, is a "differentiated / de-risked asset," Rama tells investors in a research note. He reiterates an Overweight rating on Amicus.
News For FOLD From the Last 2 Days
There are no results for your query FOLD